The S&P 500 Welcomes Lululemon: Is This a Game-Changer for the Stock?
Investors need to learn what to watch and how to be mentally prepared for what could be coming.
You Don’t Have to Pick a Winner in Fintech. Here’s Why
Investors can look at numerous businesses that use tech to improve financial services.
The Rise and Fall of Enphase Energy: Lessons Learned
Enphase Energy was a hot stock until the past year, when it dropped. What happened?
Nvidia’s Stock Is Incredibly Expensive. Here’s Why it Could Still Go Higher.
There’s plenty of growth potential on the horizon for this rapidly growing business.
3 Signs It’s Time to Change Your Medicare Advantage Plan
A new plan could offer better coverage or result in savings.
BlackRock’s Long-Term Investments Had $12.6 Billion in Net Outflows. Should Investors Be Concerned?
The world’s largest asset manager saw assets under management drop in the quarter. Here’s what investors need to know.
Got $1,000? Here Are 3 Ways to Turn It Into $75 or More of Annual Income.
These companies offer dividends yielding more than 7.5%.
Where Will Palantir Technologies Stock Be in 5 Years?
A new catalyst could send this high-flying tech stock soaring over the next five years.
1 Magnificent Warren Buffett Stock to Buy Hand Over Fist Right Now
Investors need to take a closer look at this dominant tech business.
This Top Marijuana Stock Is Making a Big Move to a Major Exchange
Curaleaf could be the latest U.S. pot stock to hit the Toronto Stock Exchange. Will others follow?
The Once-in-a-Generation $1 Trillion Opportunity You Won’t Want to Miss
Four catalysts are driving robust demand for data centers.
Did Microsoft Waste $69 Billion on Activision Blizzard?
The software giant paid a big premium while making compromises to gain regulatory approval.
Nvidia Is Doubling Its Pace of Innovation: Will It Leave Challengers in the Dust?
Nvidia just released a product roadmap set to propel it ahead of would-be AI challengers.
If You Ask Me, Delaying Social Security Is Overrated — Here’s Why
Years of missed payments may not be worth the increased payouts from delaying benefits.
This Cathie Wood Stock Could Soar 140%, Wall Street Says. Is That Too Optimistic?
Some of the world’s biggest pharma companies are partnering with Ginkgo.
53.7% of Warren Buffett’s $344 Billion Berkshire Hathaway Portfolio Is Invested in These 2 Dividend Stocks
Buffett thinks these dividend stocks have what it takes to be long-term winners.
Cathie Wood Just Added $5 Million of This Stock After It Had a Steep Pullback. Is It a No-Brainer Buy?
This innovator is targeting a huge, rapidly growing market.
Is the “New” Johnson & Johnson Stock a Buy With Its Improved Profit Outlook?
Some things are different about J&J. But other things remain the same as they’ve been for a long time.
Genetic risk scores not useful in predicting disease
A new study looked at 926 polygenic risk scores for 310 diseases. It found that, on average, only 11% of individuals who develop disease are identified, while at the same time 5% of people who do not develop the disease test positive. Unaffected people…
Team finds a stem-cell derived mechanism that could lead to regenerative therapies for heart damage
A team has identified an essential internal control mechanism that can promote the maturation of human stem cell-derived heart muscle cells, possibly leading to new therapies for heart disease and cardiac damage.